HS-130: The first allogeneic, off-the-shelf cell therapy that delivers localized OX40-mediated co-stimulation to enhance T-cell activation

HS-130 is the company’s allogeneic (“off-the-shelf”) cell line engineered to express OX40 ligand fusion protein (OX40L-Fc). OX40 ligand is a key co-stimulator of T cells that augments antigen-specific CD8+ T cell responses.

Improved efficacy and safety were demonstrated in multiple preclinical cancer models using OX40L-Fc via cell-based delivery compared to systemic administration of an OX40 agonist antibody in combination with HS-110. A phase 1 clinical trial has been initiated.

Visit www.clinicaltrials.gov for more details

Program Mechanism of Action
Indication Preclinical Phase 1 Phase 2 Phase 3


(Cell Therapy)
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started